News Medivir AB

Equities

MVIR B

SE0020181014

Delayed Nasdaq Stockholm Other stock markets 07:34:58 2024-04-26 am EDT			5-day change	1st Jan Change
2.91 ^SEK	-4.59%		+8.99%	+2.11%

Apr. 25	Medivir Gets Two US FDA Designations for MIV-711	MT
Mar. 21	Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioStock: Medivir optimizes study design after meeting FDA	06:46am	AQ
Medivir Gets Two US FDA Designations for MIV-711	Apr. 25	MT
Medivir : FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease	Apr. 25	PU
FDA grants Medivir's MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease	Apr. 25	AQ
Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue	Apr. 23	AQ
BioStock: Medivir's partner makes clinical progress in veterinary project	Apr. 19	AQ
Medivir : The Board of Directors statement under Chapter 19 Section 22 of the Swedish Companies Act	Apr. 16	PU
Medivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701	Apr. 15	AQ
BioStock: Medivir continues to accelerate development with fostrox	Apr. 12	AQ
Medivir : The Nomination Committees proposal for the AGM	Apr. 09	PU
Medivir to present at Investing in Oncology Forum on April 10	Apr. 09	AQ
Medivir : Corporate Governance Report	Apr. 05	PU
Medivir 2023 Annual Report published	Apr. 04	AQ
Medivir : Notice of AGM 2024	Apr. 04	PU
Notice of Annual General Meeting of Medivir AB (publ)	Apr. 04	AQ
Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	Mar. 20	CI
Medivir to present at Swiss Nordic Bio in Zürich on March 7	Mar. 06	AQ
Medivir to present at the Life Science Day in Gothenburg on March 6	Mar. 04	AQ
Change in Medivir's nomination committee before the 2024 AGM	Feb. 26	AQ
Medivir presents data that strengthens the fostrox/Lenvima combination in primary liver cancer at EASL Liver Cancer Summit	Feb. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Medivir AB

Equities

MVIR B

SE0020181014

Summary

Filters